Abiopharma

🔍 Watts Ryan J. (Director)

Company: Denali Therapeutics Inc. (DNLI)

Report Date: 2026-01-03

Detailed Transactions and Holdings:

• Acquired 78,960 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: A | equity_swap_involved: 0 | shares_owned_after: 332,031.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 2,152,604.00 | Footnotes: F3
• Acquired 236,880 shares of Stock Option (right to buy) at $16.27 per share (Derivative)
  Date: 2026-01-03 | Code: A | Expires: 2036-01-03 | equity_swap_involved: 0 | shares_owned_after: 236,880.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
• F2: Includes 184,915 Unvested RSUs.
• F3: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
• F4: 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date